Featured Story

  • Intercept Pharma soars after nabbing 'breakthrough' title for blockbuster NASH contender

    Intercept Pharmaceuticals has nabbed the FDA's breakthrough therapy designation (BTD) for obeticholic acid (OCA), a closely watched therapy in the pipeline for a blockbuster NASH indication. The biotech says the BTD win was based on data from a pair of midstage studies of OCA, which persuaded some analysts to tap it as a major new therapy in the clinic for a rapidly growing population of patients suffering from liver disease. While no guarantee of success, the agency has been handing out BTDs as a hall pass for companies looking for quick access and feedback from the agency. In this case, the company says a breakthrough designation should help grease the tracks for the late-stage program. Read more >>

Spark nails a $161M IPO to fund its 'breakthrough' gene therapy

Spark Therapeutics, at work on one-time treatments for rare diseases, pulled off a $161 million IPO, pricing above its range and keeping biotech's Wall Street hot streak rolling.

Obama wants $215M to kick off 'precision medicine' project

President Barack Obama is asking Congress for $215 million to sequence the genomes of 1 million Americans and help develop a new generation of medicines, part of a sweeping plan to accelerate biomedical R&D.

Astellas bets on Immunomic's allergy vaccine in a $75M deal

Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan.

Pfizer bails on a $70M rare disease deal with Repligen

Pfizer is walking away from a $70 million collaboration with Waltham, MA's Repligen, handing back some early-stage treatments for the rare spinal muscular atrophy.

Tracon raises $36M in a downsized IPO

Cancer drug developer Tracon Pharmaceuticals pulled in $36 million in an IPO, pricing well below its expected range as it works to get its top drug into late-stage trials.


From Our Sister Sites


As the med tech industry homes in on next-generation devices for peripheral artery disease, medical experts are questioning the necessity of procedures to treat the disease, pointing to large Medicare payments made to physicians performing the operations.


Scientists in Florida have found a virus in ticks that is connected to hemorrhagic fever, which was thought to have disappeared globally more than 40 years ago.